Inspire Medical Systems Future Growth
Future criteria checks 4/6
Inspire Medical Systems is forecast to grow earnings and revenue by 34% and 16.1% per annum respectively. EPS is expected to grow by 32.7% per annum. Return on equity is forecast to be 8.5% in 3 years.
Key information
34.0%
Earnings growth rate
32.7%
EPS growth rate
| Medical Equipment earnings growth | 16.8% |
| Revenue growth rate | 16.1% |
| Future return on equity | 8.5% |
| Analyst coverage | Good |
| Last updated | 22 Dec 2024 |
Recent future growth updates
Recent updates
Getting In Cheap On Inspire Medical Systems, Inc. (NYSE:INSP) Might Be Difficult
Dec 11
Inspire Medical Systems: Getting Cheaper But Not There Yet
Nov 23Inspire Medical Systems, Inc. Just Recorded A 894% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 07A Look At The Intrinsic Value Of Inspire Medical Systems, Inc. (NYSE:INSP)
Oct 31Is Now The Time To Look At Buying Inspire Medical Systems, Inc. (NYSE:INSP)?
Oct 03After Leaping 39% Inspire Medical Systems, Inc. (NYSE:INSP) Shares Are Not Flying Under The Radar
Aug 08Is Inspire Medical Systems, Inc. (NYSE:INSP) Trading At A 39% Discount?
Jul 17At US$162, Is It Time To Put Inspire Medical Systems, Inc. (NYSE:INSP) On Your Watch List?
Jun 22Inspire Medical Systems, Inc.'s (NYSE:INSP) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
May 09Inspire Medical Systems: A Potential Example Of Market Mispricing
Apr 05Inspire Medical Systems, Inc. (NYSE:INSP) Shares Could Be 23% Below Their Intrinsic Value Estimate
Mar 27Is There Now An Opportunity In Inspire Medical Systems, Inc. (NYSE:INSP)?
Mar 06Inspire Medical: A Good Night Sleep
Feb 08Inspire Medical Systems: Time To Wake Up
Nov 17Inspire Medical Systems: Stock In A Deep Sleep Despite Stellar Sales Growth
Oct 25Inspire Medical Systems: Excellent Execution And Reset Valuation
Aug 17Inspire Medical Systems: Revolutionizing Obstructive Sleep Apnea Treatment
Jul 19Inspire Medical Systems: Valuation, Sentiment, Fundamental Factors Call For Re-Rating
Jun 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,123 | 89 | 201 | 204 | 13 |
| 12/31/2025 | 951 | 60 | 164 | 161 | 17 |
| 12/31/2024 | 796 | 40 | 131 | 110 | 17 |
| 9/30/2024 | 756 | 33 | 38 | 78 | N/A |
| 6/30/2024 | 706 | 6 | -9 | 30 | N/A |
| 3/31/2024 | 661 | -16 | 3 | 35 | N/A |
| 12/31/2023 | 625 | -21 | 1 | 25 | N/A |
| 9/30/2023 | 570 | -33 | 8 | 27 | N/A |
| 6/30/2023 | 526 | -41 | 19 | 34 | N/A |
| 3/31/2023 | 466 | -44 | 11 | 23 | N/A |
| 12/31/2022 | 408 | -45 | 2 | 12 | N/A |
| 9/30/2022 | 348 | -50 | -14 | -7 | N/A |
| 6/30/2022 | 301 | -44 | -23 | -18 | N/A |
| 3/31/2022 | 262 | -43 | -27 | -22 | N/A |
| 12/31/2021 | 233 | -42 | -25 | -20 | N/A |
| 9/30/2021 | 201 | -47 | -30 | -25 | N/A |
| 6/30/2021 | 175 | -47 | -38 | -34 | N/A |
| 3/31/2021 | 134 | -57 | -52 | -49 | N/A |
| 12/31/2020 | 115 | -57 | -55 | -53 | N/A |
| 9/30/2020 | 96 | -59 | -57 | -55 | N/A |
| 6/30/2020 | 81 | -57 | -51 | -49 | N/A |
| 3/31/2020 | 87 | -41 | -39 | -37 | N/A |
| 12/31/2019 | 82 | -33 | -36 | -33 | N/A |
| 9/30/2019 | 72 | -29 | -32 | -29 | N/A |
| 6/30/2019 | 64 | -25 | -31 | -30 | N/A |
| 3/31/2019 | 57 | -24 | -24 | -23 | N/A |
| 12/31/2018 | 51 | -22 | -19 | -19 | N/A |
| 9/30/2018 | 44 | -21 | -20 | -19 | N/A |
| 6/30/2018 | 38 | -21 | N/A | -19 | N/A |
| 3/31/2018 | 33 | -20 | N/A | -17 | N/A |
| 12/31/2017 | 29 | -18 | N/A | -16 | N/A |
| 12/31/2016 | 16 | -19 | N/A | -18 | N/A |
| 12/31/2015 | 8 | -21 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSP's forecast earnings growth (34% per year) is above the savings rate (2.6%).
Earnings vs Market: INSP's earnings (34% per year) are forecast to grow faster than the US market (15.3% per year).
High Growth Earnings: INSP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INSP's revenue (16.1% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: INSP's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSP's Return on Equity is forecast to be low in 3 years time (8.5%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 03:36 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Inspire Medical Systems, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| David Rescott | Baird |
| Ravi Misra | Berenberg |